Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 7/20 | 0.37 |
| ▸ | KLK5 | Q9Y337 | 6/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.34 |
| ▸ | CETP | P11597 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | STS | P08842 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4555170 | 0.79 | GPR119 (0.37) | KLK7KLK5JAK2JAK1STS | |
| SCHEMBL15519210 | 0.71 | RIPK1 (0.38) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL7067385 | 0.71 | GPR119 (0.36) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL7515485 | 0.71 | GPR119 (0.36) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL12888044 | 0.70 | KLK7 (0.46) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL6494880 | 0.70 | KLK7 (0.36) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL18597763 | 0.69 | USP30 (0.40) | KLK7KLK5STSGPR119KDM4E | |
| SCHEMBL11996752 | 0.69 | USP30 (0.40) | KLK7KLK5STSGPR119KDM4E | |
| SCHEMBL18597764 | 0.69 | USP30 (0.40) | KLK7KLK5STSGPR119KDM4E | |
| SCHEMBL31486301 | 0.69 | FKBP1A (0.44) | KLK7KLK5PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038030-A1 | Amino-bicyclic pyrazinones and pyridinones as coagulation serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038030-A1 | Amino-bicyclic pyrazinones and pyridinones as coagulation serine protease inhibitors | TFPI, F5, F2 | KLK7 203/4885KLK5 108/4885PRSS1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.